Tesamorelin is a growth-hormone-releasing hormone analogue: the full 44-residue GHRH sequence with a trans-3-hexenoyl group at the N-terminus that resists enzymatic cleavage. At 5135.89 Da it is the largest peptide in this catalogue, and its value in the laboratory is as a characterised GHRH receptor agonist and a reference standard for analytical methods on long chains. The material is supplied for laboratory research only.
PEPTIDE · RESEARCH MONOGRAPH · SYNTHETIC GHRH(1-44) ANALOG, TRANS-3-HEXENOIC ACID MODIFIED
Mechanisms described in the published preclinical literature.
A synthetic trans-3-hexenoic acid-modified analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth hormone secretion while preserving the normal pulsatile release pattern, unlike administered growth hormone.
Growth hormone released downstream of the GHRH receptor activates hormone-sensitive lipase in adipocytes. This is the signalling route described in the class literature, characterised in adipocyte and animal preparations.
The trans-3-hexenoyl group at the N-terminus resists cleavage by dipeptidyl peptidase-4, the enzyme that inactivates native GHRH. That modification is the structural difference between this compound and the native 44-residue sequence.
Findings from the published literature, as the studies reported them. Where a finding comes from a human trial, it says so. None is a claim about the material supplied here.
Native GHRH was isolated and sequenced in 1982 as a 44-residue peptide. This compound retains that full sequence, which sets it apart from the 29-residue fragments used elsewhere in GHRH receptor research.
Guillemin R et al. 1982
Non-clinical pharmacology characterised the compound's activity at the pituitary GHRH receptor and the downstream rise in growth hormone and IGF-1 in animal models.
Ferdinandi ES et al. 2007
The N-terminal trans-3-hexenoyl group was introduced to resist dipeptidyl peptidase-4, the main route by which native GHRH is inactivated in plasma preparations.
Ferdinandi ES et al. 2007
At 44 residues and 5135.89 Da it serves as a characterised standard when developing RP-HPLC and LC-MS methods for long peptide chains, where coupling failures accumulate and closely related impurities are hard to resolve.
Rivier J et al. 1982
It is a stabilised analog of the body's own growth hormone-releasing hormone. Rather than supplying growth hormone directly, it prompts the pituitary to release its own, which preserves the natural pulsatile rhythm that administered growth hormone overrides.
No. It is a research reference standard released against a certificate of analysis for in-vitro work. It is not manufactured or released as a pharmaceutical, carries no approval of any kind, and is not for human or veterinary use.
By LC-MS against the expected molecular weight of 5135.89 Da, alongside RP-HPLC for purity. Both results are on each lot's certificate of analysis, published in the COA library.
Because it keeps the full 44-residue GHRH sequence rather than the 29-residue fragment used in related compounds. Every extra coupling step in synthesis lowers yield and makes purification harder, which is also why it costs more than shorter peptides.
The trans-3-hexenoyl group protects the N-terminus from dipeptidyl peptidase-4, the enzyme that cuts native GHRH between its second and third residues. It is the structural feature that distinguishes the compound from the native sequence.
Store the sealed vial at −20°C for long-term stability. Once reconstituted, hold at 2–8°C and protect from light; we do not publish an in-use shelf life for reconstituted material because we have not measured one on this material. Protect from light and avoid repeated freeze-thaw cycles.
Each entry opens a PubMed search for that title rather than a fixed identifier, so the link resolves to the current record.
For laboratory research use only. Not a drug, supplement or medical product, and not for human or animal use. Every finding referenced on this page comes from published preclinical or laboratory research and is not a claim about this product.
